Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (1531)	4/10/1998 8:38:00 PM
From: Bob L	Read Replies (1) \| Respond to of 1762

Glad you enjoy my Yahoo posts, Maurice. I'm not so popular over there. For that matter, neither are you. Did the doctors flat out say Rituxan would be ineffective for intermediate grade, or did they just steer you towards what they think is the better choice, the more established treatments?

To: Maurice Winn who wrote (1531)	4/12/1998 12:48:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1762

Maurice: I am interested in CLTR, IDPH, and TCLN. Have owned IDPH on at least a couple of occasions and CLTR once. You lost me with "It isn't that I don't think CD20 MAbs won't be ineffective" I don't understand what you are trying to say. I think that's a quadruple negative, and that you've broken my old record. ;-) Cancernet doesn't list all trials..... and, it is my understanding that GNE is testing Rituxan in additional B cell malignancies. From the recent IDPH 10-Q....... "In an effort to identify expanded applications for Rituxan, the Company, in conjunction with Genentech, has authorized over 35 Rituxan post-marketing trials to date. Several of these trials will explore the use of Rituxan in a variety of investigational B-cell non-Hodgkins lymphoma clinical settings including: (i) combination therapy with widely used chemotherapy regimens for both low grade and intermediate/high grade disease; (ii) single agent therapy in newly diagnosed, previously untreated low grade disease; (iii) integration into autologous bone marrow transplant regimens both as an in-vivo purging agent prior to bone marrow harvest and post-transplant as consolidation therapy; and (iv) treatment of AIDS-related lymphoma. Additionally, clinical trials will be initiated in other B-cell malignancies and pre-malignant conditions such as chronic lymphocyte leukemia ("CLL"), multiple myeloma and lymphoproliferative disorders associated with solid organ transplant therapies." and....... "Ongoing or completed Phase II studies suggest that Rituxan may also be useful in combination with chemotherapy in low grade or follicular lymphomas, and as a single agent, or in combination with various chemotherapies, in the treatment of other forms of non-Hodgkin's lymphoma." Am I missing your point? Cheers! Rick